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the recent rise of companies that offer genetic testing directly to consum-ers, bypassing the traditional face-
to-face consultation with a health-care 
professional, has created a steady stream of 
debate over the actual and potential value 
of these services (Hogarth et al, 2008). 
Despite the debates, however, the real-
ity remains that these services are being 
offered and have genuine consequences 
for consumers. as opposed to the issues 
that have regularly been discussed regard-
ing direct- to- consumer (Dtc) genetic 
testing, the fact that these companies use 
consumers’ data to perform research has 
been given relatively little attention. this 
omission is misconceived as this practice—
within the wider realm of Dtc genetic 
testing services—raises its own questions 
and concerns. in particular, it is blurring 
the line between consumers and research 
subjects, which threatens to undermine 
the public trust and confidence in genetic 
research that the scientific community has 
been trying to build over the past decades.
With this in mind, we analysed the web-
site s—including informed consent forms 
and privacy policies—of five companies that 
offer Dtc full genome testing: 23andMe, 
decoDE, navigenics, gene Essence—the 
genetic testing service offered by the com-
pany BioMarker pharmaceuticals—and 
SeqWright. two questions guided our study: 
are consumers aware that the data gener-
ated by the company to fulfil the terms of 
their service will later be used for research? 
Even if this is the case, is the process of 
consent provided by companies ethi-
cally acceptable from the point of view of 
academic research?
as there are no empirical data avail-able to answer the first question, we turned to the websites of the com-
panies to understand how explicitly they 
present their research activities. at the time 
of the study—from July 2009 to January 
2010—23andMe, decoDE and navigenics 
candidly revealed on their websites that 
they conduct research using consumer 
data (Sidebar a). By contrast, SeqWright 
and gene Essence provided what we 
identified as indirect and even ambiguous 
information about their research activities. 
For example, in a SeqWright online order 
form, the company notes: “please volun-
teer any diseases from which you currently 
suffer (this can help us advance medical 
research by enabling us [sic] discover new 
Snp [single nucleotide polymorphism]/
Disease associations)”. the information in 
gene Essence’s privacy policy was similarly 
vague (http://geneessence.com/our-labs/
privacy-policy.html), stating that “electing 
to provide optional profile information 
may enable the company to advance the 
science of genetics and provide you with 
an even better understanding of who you 
are genetically”.
if, as appears to be the case, these state-
ments are the only declarations offered 
by these two companies alluding to their 
presumed research activities, it is virtually 
impossible for consumers to understand that 
their data will be used for research purposes. 
Moreover, despite the fact that the three 
other companies do state that they con-
duct research using consumer genotypes, 
even their declarations still give cause for 
concern. For instance, both navigenics and 
decoDE ‘tuck away’ most of the informa-
tion in their terms of service agreements, 
privacy policies, or in the informed consent 
sections of their websites. this is worrisome, 
as most consumers do not even read and/
or understand the ‘legalese’ or ‘small print’ 
when signing online forms (ico, 2008).
Even when a company is relatively transparent about its research activi-ties, one might still be concerned by a 
lack of consumer awareness of these activi-
ties. Between July and September 2009, 
23andMe offered a new service called the 
“23andMe research edition”, which was 
prominently displayed on the company 
website. this version of their service, which 
was part of what the company calls the 
“23andMe research revolution”, was offered 
for uS$99—one-quarter of the price of their 
traditional personal genome scan—and it 
offered less information to consumers than 
the “traditional” service. For instance, the 
abridged research edition neither offered 
information about carrier status, pharmaco-
genomic information and ancestry, nor could 
the customer browse or download the raw 
genomic data (https://www.23andme.com/ 
researchrevolution/compare).
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at a glance, it seemed that 23andMe were 
marketing the “research edition” as a more 
affordable option, owing to the fact that the 
consumers were being given less informa-
tion and because its name implied that the 
data would be used for research. granted, 
the company did not explicitly express this 
last assumption, but the term “research edi-
tion” could have easily led consumers to this 
conclusion. However, what is particularly 
troubling about the two options—“research 
edition” and “traditional”, presented as dis-
tinct products—is that the consent forms 
for both services were identical. the issue 
is therefore whether, by calling one option 
“research edition”, 23andMe made it less 
clear to individuals purchasing the “tradi-
tional” service that their data would also be 
used for research purposes.
Even were we assured that consum-ers are at least aware of the research being conducted, we must still ask 
whether the companies are obtaining ade-
quate consent compared with that required 
from volunteers for similar research stud-
ies? to answer this question, we consid-
ered official guidelines covering consent, 
public views on the topic and information 
gleaned from the websites of Dtc genetic 
testing companies. 
concerning public opinion, many stud-
ies show that participants who have agreed 
to have their tissue used for one type of 
research do not necessarily automatically 
agree to take part in other studies (goodson 
& Vernon, 2004; Schwartz et al, 2001). 
Furthermore, in a survey of more than 1,000 
patients, 72% considered it important to 
be notified when leftover blood taken for 
clinical use was to be used for research 
(Hull et al, 2008). Most of those patients 
who wanted to be notified would require 
the researchers to get permission for other 
research (Hull et al, 2008).
although some of the companies in our 
study do mention the diseases that they 
might study, they are not specific and do not 
describe the scope of the research that will 
be done. indeed, beyond the initial customer 
signature required to complete the purchase 
of the genetic testing service, it is not always 
clear whether the companies would ever 
contact consumers to obtain explicit consent 
for internally conducted research. that said, 
if they were to send out surveys or question-
naires to request supplementary phenotype 
information, and consumers were to fill 
out and return those forms, the companies 
might consider this as consent to research. 
We would argue, however, that this blurs the 
line between individuals as consumers and 
as research participants: requesting addi-
tional information could still be understood 
by consumers as an additional service that 
they purchased and not an explicit invitation 
to take part in research.
the issue of the identifiability of genomic 
data is inextricably related to the issue of 
consent as “[p]romises of anonymity and 
privacy are important to a small but signifi-
cant proportion of potential participants” 
(andrews, 2009). in the study performed by 
Hull and colleagues, 23% of participants dif-
ferentiated between scenarios where sam-
ples and data were stored anonymously or 
with identifiers (Hull et al, 2008). the issue 
of anonymity is particularly important under 
the uS common rule definition of ‘human 
subject’ research (HHS, 2009). it dictates 
that research conducted using samples from 
people that cannot be identified is not con-
sidered human subject research and as such 
does not require consent. although this rule 
applies only to federally funded research, it 
might become pertinent if companies collab-
orate with publicly funded institutions, such 
as universities. More generally, regulations 
such as the common rule and the uS Food 
and Drug administration’s regulations for the 
protection of human subjects highlight the 
importance of the protection of individuals 
in research. research activities conducted 
by companies selling Dtc genetic tests 
should therefore be similarly transparent and 
accountable to a regulatory body.
on the basis of the information from the 
websites of the companies we surveyed, it is 
not unambiguously clear whether the data 
used in their research is anonymized or not. 
that said, 23andMe claims it will keep con-
sumers informed of future advancements in 
science and might ask them for additional 
phenotype information, suggesting that it 
maintains the link between genotype data 
and the personal information of its custo-
mers. as such, research conducted by 
23andMe could be considered to involve 
human subjects. thus, if 23andMe were 
to comply voluntarily with the common 
rule, they would have to obtain adequate 
informed consent.
Even in cases in which data or samples 
are anonymized, studies show that people 
do care about what happens to their sam-
ple (Hull et al, 2008; Schwartz et al, 2001). 
Furthermore, it is becoming more and more 
apparent that there are intrinsic limits to the 
degree of protection that can be achieved 
through sample and data de-identification 
and anonymization in genomic research 
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Sidebar A | Information provided by direct-to-consumer genetic testing companies*
23andMe
“You understand that your genetic and other contributed personal information will be stored in 
23andMe research databases, and authorized personnel of 23andMe will conduct research using said 
databases.” (https://www.23andme.com/about/consent; accessed 29 January 2010)
deCODE
“Information that you provide about yourself under the security of your account and privacy of your 
chosen username may be used by deCODEme only to gather statistical aggregate information about the 
users of the deCODEme website. Such analysis may include information that we would like to be able to 
report back to you and other users of deCODEme, such as in counting the number of users grouped by 
gender or age, or associating genetic variants with any of the self-reported user attributes. In any such 
analyses and in presenting any such statistical information, deCODE will ensure that user identities are 
not exposed.” (http://www.decodeme.com/faq; accessed 29 January 2010)
Navigenics
“Navigenics is continuously improving the quality of our service, and we strive to contribute to 
scientific and medical research. To that end, we might de-link Your Genetic Data and Your Phenotype 
Information and combine it with other members’ information so that we can perform research to: […] 
Discover or validate associations between certain genetic variations and certain health conditions or 
traits, as well as other insights regarding human health.” (http://www.navigenics.com/visitor/ 
what_we_offer/our_policies/informed_consent/health_compass; accessed 29 January 2010)
*See main text for information from SeqWright and Gene Essence.
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(Homer et al, 2008; lin et al, 2004; Mcguire 
& gibbs, 2006; p3g consortium et al, 2009). 
this further weakens the adequacy of com-
panies obtaining broad-sense consent from 
consumers who, most probably, are not even 
aware that research is being conducted.
the European Society of Human genetics (ESHg) has recently issued a statement on Dtc genetic testing for 
health-related purposes, which states that 
“[t]he ESHg is concerned with the inad-
equate consent process through which 
customers are enrolled in such research. 
if samples or data are to be used in any 
research, this should be clear to consumers, 
and a separate and unambiguous consent 
procedure should take place” (ESHg, 2010). 
another document was recently drafted 
by the uK Human genetics commission 
(Hgc), entitled ‘common Framework of 
principles for Direct-to-consumers genetic 
testing Services’ (Hgc, 2009). the prin-
ciples were written with the intention of 
promoting high standards and consistency 
in the Dtc genetic testing market and to 
protect the interests of consumers and their 
families. although this document is not 
finalized and the principles themselves 
cannot control or regulate the market in any 
tangible way, this framework, along with the 
ESHg statement, constitute the most up-to-
date and exhaustive documents addressing 
Dtc genetic testing activities.
principle 4.5 states: “if a test provider 
intends to use a consumer’s biological sam-
ples and/or associated personal or genetic 
data for research purposes, the consumer 
should be informed whether the research 
has been approved by a research ethics 
committee or other competent authority, 
whether the biological sample and data 
will be transferred to or kept in a biobank or 
database, and about measures to ensure the 
security of the sample. the consumer should 
be informed of any risks or potential benefits 
associated with participating in the research.” 
principle 5.6 of the Hgc’s draft states that 
a “[s]eparate informed consent should be 
requested by the test provider before bio-
logical samples are used for any secondary 
purposes, e.g research, or before any third 
party is permitted access to bio logical sam-
ples. consumers’ biological samples and 
personal and genetic data should only be 
used for research that has been approved by 
a research ethics committee (rEc) or other 
relevant competent authority.”
none of the companies we surveyed 
reveal on their websites whether internal 
research protocols have been approved by 
a rEc or by an independent “competent 
authority”. Furthermore, no such inde-
pendent body exists that deals specifically 
with the research activities of commer-
cial companies selling Dtc genetic tests. 
additionally, if a company did claim to have 
internal ethical oversight, it would be ques-
tionable whether such a committee would 
really have any power to veto or change the 
company’s research activities.
Moreover, while all five companies do state what will happen to the Dna sample —in most cases, 
unless asked otherwise by the consumer, 
the Dna sample will be destroyed shortly 
after testing—not enough is revealed 
about what will happen to the data. Some 
companies say where data is kept and 
comment on the security of the website, 
but as mentioned previously, companies 
are not clear about whether data will be 
anonymized. traditionally, a great deal of 
focus has been placed on the fate and stor-
age of biological samples, but genome-
wide testing of hundreds of thousands 
of individuals for thousands or even mil-
lions of Snps generates a lot of data. this 
information is not equivalent, of course, 
to a full genome sequence, but it can fuel 
numerous genomic studies in the imme-
diate and medium-term future. as such, 
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additional issues above and beyond basic 
informed consent also become a concern. 
For instance, what will happen to the data 
if a company goes bankrupt or is sold? 
Will the participants be sent new consent 
forms if the nature of the company or the 
research project changes drastically?
the activities of companies offering Dtc genetic testing have not only blurred the lines between medical 
services and consumer products, but also 
between these two activities and research. 
as a consequence, the appropriate treat-
ment and autonomy of individuals who pur-
chase Dtc genetic testing services could be 
undermined. paramount to this issue is the 
fact that companies should be completely 
transparent with the public about whether 
people purchasing their tests are consum-
ers or research subjects or both. although an 
individual who reads through the websites of 
such companies might be considered a sim-
ple ‘browser’ of the website, once the terms 
and conditions are signed—irrespective of 
an actual reading or comprehension—the 
curious consumer becomes a client and a 
research subject.
companies using consumer samples 
and data to conduct research are in essence 
creating databases of information that can 
be mined and studied in the same way as 
biobanks and databases generated by aca-
demic institutions. as such, consumers who 
become research participants should be 
treated with the same respect and under the 
same norms as those involved in biobank 
research. as stated by the organization for 
Economic co-operation and Development, 
research should “respect the participants 
and be conducted in a manner that upholds 
human dignity, fundamental freedoms and 
human rights and be carried out by responsi-
ble researchers” (oEcD, 2009). on the basis 
of our analysis of the websites of five compa-
nies offering Dtc full genome testing, there 
is little evidence that the participation of 
‘consumers’ in research is fully informed.
the analysis of company websites was 
conducted in 2009 and early 2010. the 
information offered to consumers by the 
companies mentioned in this outlook 
might have changed following the study’s 
completion or the article’s publication.
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